Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Novartis Pharmaceuticals UK Ltd
Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR
Telephone: +44 (0)1276 692 255
Fax: +44 (0)1276 698 449
Medical Information Direct Line: +44 (0)1276 698 370
Medical Information e-mail: medinfo.uk@novartis.com
Customer Care direct line: +44 (0)845 741 9442

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Patient Information Leaflet last updated on the eMC: 06/09/2011
PIL VISUDYNE 15 mg, powder for solution for infusion

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 06/09/2011 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change of manufacturer
Updated on 26/05/2010 and displayed until 06/09/2011
Reasons for adding or updating:
  • Change due to harmonisation of PIL.
Updated on 31/07/2008 and displayed until 26/05/2010
Reasons for adding or updating:
  • Change to side-effects
  • Change to information about pregnancy or lactation
Updated on 26/06/2007 and displayed until 31/07/2008
Reasons for adding or updating:
  • Change to, or new, use for medicine
Updated on 07/01/2005 and displayed until 26/06/2007
Reasons for adding or updating:
  • Change of manufacturer
Updated on 03/03/2004 and displayed until 07/01/2005
Reasons for adding or updating:
  • Update to PIL
Updated on 27/09/2002 and displayed until 03/03/2004
Reasons for adding or updating:
  • Update to PIL
Updated on 21/05/2001 and displayed until 27/09/2002
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
  verteporfin